A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer

Published:2024 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Gupta Abha A.,Tinker Anna V.,Jonker Derek,Jamal Rahima,Hirte Hal,Winquist Eric,Chu Quincy,Kollmannsberger Christian K.,Wong Ralph,Alcindor Thierry,Nielsen Torsten O.,Tsao Ming,Cottrell Tricia R.,Provencher Diane,Hilton John,Krzyzanowska Monika,Elser Christine,Hotte Sebastien,Sederias Joanna,Zhang Siwei,Tu Wei,Dancey Janet

Publisher

Elsevier BV

Reference78 articles.

1. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways;B T Fife;Immunol Rev,2008

2. PD-1-targeted immunotherapy: recent clinical findings;J R Brahmer;Clin Adv Hematol Oncol,2012

3. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma;Amm Eggermont;N Engl J Med,2018

4. The blockade of immune checkpoints in cancer immunotherapy;D M Pardoll;Nat Rev Cancer,2012

5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma;J Weber;N Engl J Med,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP